Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023.
Effectiveness and safety of vaccines, medicines and health products - Quality of medical laboratories
Download 319.45 KBAuthors
Mario Fontán-Vela [3]; Kissling, Esther [4]; Nathalie Nicolay [5]; Toon Braeye [6]; Izaak Van Evercooren [7]; Christian Holm Hansen [8]; Hanne-Dorthe Emborg [9]; Massimo Fabiani [10]; Alberto Mateo-Urdiales [11]; Ala'a AlKerwi [12]; Susanne Schmitz [13]; Jesús Castilla [14]; Iván Martínez-Baz [15]; Brechje de Gier [16]; Susan Hahné [17]; Hinta Meijerink [18]; Jostein Starrfelt [19]; Baltazar Nunes [20]; Caetano, Constantino [21]; Tarik Derrough [22]; Anthony Nardone [23]; Susana Monge [24]Keywords
Article written during project(s) :
Abstract:
To monitor relative vaccine effectiveness (rVE) against COVID-19-related hospitalisation of the first, second and third COVID-19 booster (vs complete primary vaccination), we performed monthly Cox regression models using retrospective cohorts constructed from electronic health registries in eight European countries, October 2021-July 2023. Within 12 weeks of administration, each booster showed high rVE (≥ 70% for second and third boosters). However, as of July 2023, most of the relative benefit has waned, particularly in persons ≥ 80-years-old, while some protection remained in 65-79-year-o…